Advertisement

Grundlagen der antineoplastischen Chemotherapie

  • H. Osswald

Zusammenfassung

Der häufig verwendete Ausdruck Zytostatika definiert die Wirkungsweise der antineoplastischen Chemotherapie nur teilweise, weil eine Zytostase bzw. Kanzerostase ebenso wie die Bakteriostase biologischer Prozesse (z. B. Immunmechanismen) zur völligen Vernichtung der Zellen bedarf. Kanzerozide Eigenschaften von Chemotherapeutika werden mit dem Ausdruck Zytostatika nur unzureichend erfaßt. Hingegen schließt der Begriff der antineoplastischen Chemotherapeutika unabhängig vom Wirkungstyp alle gegen Tumoren wirksamen Substanzen ein, zumal der Wirkungstyp eines Chemotherapeutikums auch durch die erreichbare Dosierung beeinflußt wird.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Baserga R (1981) The cell cycle. N Engl J Med 304:453–459PubMedCrossRefGoogle Scholar
  2. De Vita VT Jr, Young RC, Canellos GP (1975) Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer. Cancer 35:98–110CrossRefGoogle Scholar
  3. Grundmann E (1971) Uber den Stand der experimentellen Chemotherapie in der Krebsforschung. Aktuelle Probleme der Cancerologie III. Springer, Berlin Heidelberg New York, S 130–141CrossRefGoogle Scholar
  4. Mendelsohn ML (1962) Autoradiographic analysis of cell proliferation in spontaneous breast cancer of C3H mouse. III. The growth fraction. J Natl Cancer Inst 28:1015–1029PubMedGoogle Scholar
  5. Norton L, Simon R (1977) Tumor size, sensitivity to therapy and design of treatment schedules. Cancer Treat Rep 61:1307–1317PubMedGoogle Scholar
  6. Osswald H (1973) Der heutige Stand der Grundlagenforschung in der Chemotherapie maligner Tumoren. Arch Gynecol 214:385–389Google Scholar
  7. Osswald H (1978) Potentiation of the chemotherapeutic action of antineoplastic agents by nucleosides. In: Harmon RE, Robins RK, Townsend LB (eds) Chemistry and biology of nucleosides and nucleotides. Academic Press, New York San Francisco London, pp 149–158Google Scholar
  8. Osswald H, Youssef M (1979) Suramin enhancement of the chemotherapeutic actions of cyclophosphamide or adriamycin on intramuscularly implanted Ehrlich carcinoma. Cancer Lett 6:337–343PubMedCrossRefGoogle Scholar
  9. Potter van R (1951) Sequential blocking of metabolic pathways in vivo. Proc Soc Exp Biol Med 76:41–46PubMedGoogle Scholar
  10. Rosner D, Nemoto T (1979) Sequence for developing optimal combination chemotherapy of metastatic breast cancer. Eur J Cancer 15:1197–1201PubMedCrossRefGoogle Scholar
  11. Sartorelli AC (1969) Some approaches to the therapeutic exploitation of metabolic sites of vulnerability of neoplastic cells. Cancer Res 29:2292–2299PubMedGoogle Scholar
  12. Schabel FM Jr (1971) Concepts for systemic treatment of micrometastases. Cancer 35:15–24CrossRefGoogle Scholar
  13. Schabel FM Jr, Griswold DP Jr, Corbett TH, Laster WR Jr, Mayo JG, Lloyd HH (1979) Testing therapeutic hypothesis in mice and man: Observations on the therapeutic activity against advanced solid tumors of mice treated with anticancer drugs that have demonstrated or potential clinical utility for treatment of advanced solid tumors of man. Methods Cancer Res 17:3–51Google Scholar
  14. Schmahl D, Eisenbrand G, Fiebig HH, Habs H, Habs M, Ivankovic S, Janzowski C, Osswald H, Pool BL, Port R, Preußmann R, Schmahl D, Wiessler M, Zeller WJ (Hrsg) (1981) Maligne Tumoren Entstehung - Wachstum - Chemotherapie. Editio Cantor, Aulendorf, S 480–498Google Scholar
  15. Schwartz HS, Schioppagassi G, Kanter PM (1978) Mechanism of selectivity of intercalating agents. Antibiot Chemother 23:247PubMedGoogle Scholar
  16. Singer R, Kristen K, Weidauer H, Osswald H (1980) Fünf Jahre antineoplastische Chemotherapie fortgeschrittener Mundschleimhaut- und Oropharynxkarzinome mit Vincristin, Methotrexat, Bleomycin und Nukleosid-Rescue sowie erste Erfahrungen bei Hypopharynskarzinomen. Dtsch Z Mund- Kiefer-Gesichts-Chir 4:17–22Google Scholar
  17. Skipper HE (1971) Clowes memorial lecture. Cancer Res 31:1173–1180PubMedGoogle Scholar
  18. Skipper HE, Schabel FM Jr, Wilcox WS (1964) Experimental evaluation of potential anticancer drugs. XIII. On the criteria and kinetics associated with curability of experimental leukemia. Cancer Chemother Rep 35:1–111PubMedGoogle Scholar
  19. Temin HM, Mizutani S (1970) RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 226:1211–1213PubMedCrossRefGoogle Scholar
  20. Watson JD, Crick FHC (1953) Molekular structure of nucleic acids. Nature 177:964CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1982

Authors and Affiliations

  • H. Osswald

There are no affiliations available

Personalised recommendations